Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

By Syed S Mahmood, M. Fradley, J. Cohen, A. Nohria, K. Reynolds, L. Heinzerling, R. Sullivan, R. Damrongwatanasuk, Carol L Chen, Dipti Gupta and 10 more. Journal of the American College of Cardiology, 2018

1,411 citations recorded by the source corpus.

BACKGROUND Myocarditis is an uncommon, but potentially fatal, toxicity of immune checkpoint inhibitors (ICI). Myocarditis after ICI has not been well characterized. OBJECTIVES The authors sought to understand the presentation and clinical course of ICI-associated myocarditis. METHODS After observation of sporadic ICI-associated myocarditis cases, the authors created a multicenter registry with 8 sites. From November 2013 to July 2017, there were 35 patients with ICI-associated myocarditis, who were compared to a random sample of 105 ICI-treated patients without myocarditis. Covariates of interest were extracted from medical records including the occurrence of major adverse cardiac events (MACE), defined as the composite of cardiovascular death, cardiogenic shock, cardiac arrest, and hemodynamically significant complete heart block. RESULTS The prevalence of myocarditis was 1.14% with a median time of onset of 34 days after starting ICI (inter-quartile range: 21 to 75 days). Cases were 65 ± 13 years of age, 29% were female, and 54% had no other immune-related side effects. Relative to controls, combination ICI (34% vs. 2%; p < 0.001) and diabetes (34% vs. 13%; p = 0.01) were more common in cases. Over 102 days (interquartile range: 62 to 214 days) of median follow-up, 16 (46%) developed MACE; 38% of MACE occurred with normal ejection fraction. There was a 4-fold increased risk of MACE with troponin T of ≥1.5 ng/ml (hazard ratio: 4.0; 95% confidence interval: 1.5 to 10.9; p = 0.003). Steroids were administered in 89%, and lower steroids doses were associated with higher residual troponin and higher MACE rates. CONCLUSIONS Myocarditis after ICI therapy may be more common than appreciated, occurs early after starting treatment, has a malignant course, and responds to higher steroid doses.

Subfields: Infectious Diseases, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/e906ee7c8ff6708942e46419626cece9c007ecfc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

  1. V. Ferreira
  2. J. Schulz-Menger
  3. C. Kramer
  4. G. Holmvang
  5. I. Carbone
  6. M. Friedrich
  7. L. Cooper
  8. U. Sechtem

Citations in the corpus